Viread(R) for Hepatitis B Maintains Antiviral Suppression with No Development of Resistance Through Four Years of Treatment - page 2 of 2

[Guest guest]

(continued)

Coadministration of Viread with didanosine increases didanosine concentrations.

Use with caution and monitor for evidence of didanosine toxicity (eg,

pancreatitis, neuropathy). Didanosine should be discontinued in patients who

develop didanosine-associated adverse reactions. In adults weighing >60 kg, the

didanosine dose should be reduced to 250 mg when it is coadministered with

Viread. Data are not available to recommend a dose adjustment of didanosine for

patients weighing <60 kg Coadministration of Viread with atazanavir decreases

atazanavir concentrations and increases tenofovir concentrations. Use atazanavir

with Viread only with additional ritonavir; monitor for evidence of tenofovir

toxicity. Coadministration of Viread with lopinavir/ritonavir increases

tenofovir concentrations. Monitor for evidence of tenofovir toxicity.

In controlled clinical trials in patients with chronic hepatitis B with

compensated liver disease, the most common adverse reaction (all grades) was

nausea, observed in 9 percent of patients taking Viread at week 48. Other

adverse reactions observed at week 48 in greater than 5 percent of patients

treated with Viread include abdominal pain, diarrhea, headache, dizziness,

fatigue, nasopharyngitis, back pain and skin rash.

In HBV-infected patients with decompensated liver disease, the most common

adverse reactions (all grades) reported in greater-than or equal to 10 percent

of patients treated with Viread were abdominal pain (22 percent), nausea (20

percent), insomnia (18 percent), pruritus (16 percent), vomiting (13 percent),

dizziness (13 percent), and pyrexia (11 percent).

The recommended dose for the treatment of chronic hepatitis B is 300 mg once

daily taken orally without regard to food. The dosing interval of Viread should

be adjusted and renal function closely monitored in patients with moderate and

severe renal impairment.

The parent compound of Viread was discovered through a collaborative research

effort between Dr. Antonin Holy, Institute for Organic Chemistry and

Biochemistry, Academy of Sciences of the Czech Republic (IOCB) in Prague and Dr.

DeClercq, Rega Institute for Medical Research, Katholic University in

Leuven, Belgium. The inventors of Viread have agreed to waive their right to a

royalty on sales of Viread and Truvada in Gilead Access Program countries to

ensure the product can be offered at a no-profit price in parts of the world

where the HIV/AIDS epidemic has hit the hardest.

Important Information about Hepsera (adefovir dipivoxil)

Hepsera (adefovir dipivoxil) is indicated for the treatment of chronic hepatitis

B in patients 12 years of age and older with evidence of active viral

replication and either evidence of persistent elevations in serum

aminotransferases (ALT or AST) or histologically active disease. This indication

is based on histological, virological, biochemical and serological responses in

adult patients with HBeAg-positive and HBeAg-negative chronic hepatitis B with

compensated liver function, and with clinical evidence of lamivudine-resistant

hepatitis B virus with either compensated or decompensated liver function.

For patients 12 to less than 18 years of age, the indication is based on

virological and biochemical responses in patients with HBeAg-positive chronic

hepatitis B virus infection with compensated liver function.

Severe acute exacerbations of hepatitis have been reported in patients who have

discontinued anti-hepatitis B therapy, including Hepsera. Hepatic function

should be monitored closely with both clinical and laboratory follow-up for at

least several months in patients who discontinue anti-hepatitis B therapy. If

appropriate, resumption of anti-hepatitis B therapy may be warranted.

In patients at risk of or having underlying renal dysfunction, chronic

administration of Hepsera may result in nephrotoxicity. These patients should be

monitored closely for renal function and may require dose adjustment. It is

important to monitor renal function for all patients during treatment with

Hepsera, particularly for those with pre-existing or other risks for renal

impairment and patients taking concomitant nephrotoxic agents. Patients with

renal insufficiency at baseline or during treatment may require dose adjustment.

Caution should be exercised when prescribing Hepsera to adolescents with

underlying renal dysfunction, and renal function in these patients should be

closely monitored.

HIV resistance may emerge in chronic hepatitis B patients with unrecognized or

untreated HIV infection treated with anti-hepatitis B therapies, such as therapy

with Hepsera, which may have activity against HIV. HIV antibody testing should

be offered to all HBV-infected patients before initiating therapy with Hepsera.

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases,

have been reported with the use of nucleos(t)ide analogs alone or in combination

with other antiretrovirals.

Resistance to adefovir dipivoxil can result in viral load rebound which may

result in exacerbation of hepatitis and, in the setting of diminished hepatic

function, lead to liver decompensation and possible fatal outcomes. To reduce

the risk of resistance in patients with lamivudine resistant HBV, adefovir

dipivoxil should be used in combination with lamivudine and not as adefovir

dipivoxil monotherapy. To reduce the risk of resistance in all patients

receiving adefovir dipivoxil monotherapy, a modification of treatment should be

considered if serum HBV DNA remains above 1000 copies/mL with continued

treatment.

The most common adverse reaction (less than 10 percent) in compensated disease

patients is asthenia and in pre- and post-transplantation lamivudine-resistant

liver disease patients is increased creatinine.

The recommended dose for the treatment of chronic hepatitis B is 10 mg once

daily taken orally without regard to food. The dosing interval of Hepsera should

be adjusted in patients with renal impairment.

Important Information About Truvada

Truvada is a fixed-dose combination tablet containing 200 mg of emtricitabine

(Emtriva®) and 300 mg of tenofovir disoproxil fumarate (Viread). In the United

States, Truvada is indicated in combination with other antiretroviral agents

(such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors)

for the treatment of HIV-1 infection in adults.

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases,

have been reported with the use of nucleos(t)ide analogs, including Viread, a

component of Truvada.

Truvada is not approved for the treatment of chronic hepatitis B virus (HBV)

infection. Severe acute exacerbations of hepatitis B have been reported in

patients coinfected with HIV-1 and HBV who have discontinued Truvada. Hepatic

function should be monitored closely in these patients. If appropriate,

initiation of anti-hepatitis B therapy may be warranted.

Truvada should not be coadministered with Atripla, Emtriva, Viread or

lamivudine-containing products, including Combivir® (lamivudine/zidovudine),

Epivir® or Epivir-HBV® (lamivudine), Epzicom® (abacavir

sulfate/lamivudine) or Trizivir® (abacavir sulfate/lamivudine/zidovudine). In

treatment-experienced patients, the use of Truvada should be guided by

laboratory testing and treatment history.

Emtricitabine and tenofovir are principally eliminated by the kidneys. Renal

impairment, including cases of acute renal failure and Fanconi syndrome (renal

tubular injury with severe hypophosphatemia), has been reported in association

with the use of Viread. It is recommended that creatinine clearance be

calculated in all patients prior to initiating therapy with Truvada and as

clinically appropriate during therapy.

Routine monitoring of calculated creatinine clearance and serum phosphorous

should be performed in patients at risk for renal impairment including patients

who have previously experienced renal events while receiving Hepsera®

(adefovir dipivoxil).

Dosing interval adjustment and close monitoring of renal function are

recommended in all patients with creatinine clearance 30-49 ml/min. Truvada

should be avoided with concurrent or recent use of a nephrotoxic agent. Truvada

should not be administered with Hepsera.

Coadministration of Truvada and didanosine should be undertaken with caution.

Patients should be monitored closely for didanosine-associated adverse events

and didanosine should be discontinued if these occur. Dose reduction of

didanosine should be considered, if warranted.

Patients on atazanavir and lopinavir/ritonavir plus Truvada should be monitored

for Truvada-associated adverse events and Truvada should be discontinued if

these occur. When co-administered with Truvada, it is recommended that

atazanavir be boosted with ritonavir 100 mg. Atazanavir without ritonavir should

not be co-administered with Truvada.

Decreases in bone mineral density (BMD) at the lumbar spine and hip have been

seen with the use of Viread. The effect on long-term bone health and future

fracture risk is unknown. BMD monitoring should be considered in patients with a

history of pathologic fractures or who are at risk for osteopenia. Cases of

osteomalacia (associated with proximal renal tubulopathy and which may

contribute to fractures) have been reported in association with the use of

Viread.

Changes in body fat have been observed in patients taking anti-HIV medicines.

Immune Reconstitution Syndrome has been reported in patients treated with

combination therapy, including Viread and Emtriva, and may necessitate further

evaluation and treatment.

The most common adverse reactions (incidence greater-than or equal to 10

percent) are diarrhea, nausea, fatigue, headache, dizziness, depression,

insomnia, abnormal dreams and rash.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and

commercializes innovative therapeutics in areas of unmet medical need. The

company's mission is to advance the care of patients suffering from

life-threatening diseases worldwide. Headquartered in City, California,

Gilead has operations in North America, Europe and Australia.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of

the Private Securities Litigation Reform Act of 1995, that are subject to risks,

uncertainties and other factors, including the risks that physicians may not

prescribe Viread over other existing or future HBV medications. In addition, as

Viread is used over longer periods of time by many patients with underlying

health problems, taking numerous other medicines, safety, resistance, drug

interaction or other issues may arise, which could reduce the market acceptance

of Viread. These risks, uncertainties and other factors could cause actual

results to differ materially from those referred to in the forward-looking

statements. The reader is cautioned not to rely on these forward-looking

statements. These and other risks are described in detail in Gilead's 2009

Annual report on Form 10-K and in Quarterly Reports on Form 10-Q for the first

and second quarters of 2010, as filed with the U.S. Securities and Exchange

Commission. All forward-looking statements are based on information currently

available to Gilead, and Gilead assumes no obligation to update any such

forward-looking statements.

U.S. full prescribing information for Viread is available at www.Viread.com.

U.S. full prescribing information for Truvada is available at www.Truvada.com.

U.S. full prescribing information for Hepsera is available at www.Hepsera.com.

Viread, Truvada and Hepsera are registered trademarks of Gilead Sciences, Inc.

For more information on Gilead Sciences, please visit the company's website at

www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or

1-650-574-3000.

SOURCE: Gilead Sciences, Inc.

Gilead Sciences, Inc.

O'Brien, 650-522-1936

Investors

or

Cara , 650-522-1616

Media

Copyright Business Wire 2010